We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.03% | 1,640.00 | 1,639.00 | 1,640.00 | 1,647.00 | 1,635.00 | 1,638.50 | 496,541 | 10:14:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.72 | 67.6B |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2020 12:48 | Interesting article I ask myself the same question. | montyhedge | |
14/10/2020 11:26 | Certainly gives alot to our overpaid CEO! | geckotheglorious | |
14/10/2020 10:53 | Don't you just love GSK, the stock that keeps giving. I like the February dividend 23p. | montyhedge | |
14/10/2020 10:38 | 4 weeks to go till holders qualify for next GSK dividend..... ;0) | tradermichael | |
14/10/2020 10:01 | "Lilly’s proposed treatment is intended for hospitalized patients with severe cases of COVID-19. It is similar to the treatment made by Regeneron that was given to President Trump earlier this month. The trial is testing a combination of two lab-engineered immune system proteins called monoclonal antibodies to treat severely ill patients with coronavirus. Eli Lilly said the trial’s Data Safety Monitoring Board (DSMB) recommended the pause". (Not a vaccine candidate). | alphorn | |
14/10/2020 09:57 | https://www.independ | montyhedge | |
14/10/2020 09:43 | mh - Lilly's compound is not a vaccine. | alphorn | |
14/10/2020 09:41 | The latest to fall at the fence Lily. The final furlong will be Astra and GSK coming up to the winning post.Don't forget GSK have two runners, they are supplying tech know how to a Chinese Bio company. | montyhedge | |
14/10/2020 09:18 | Monty "Gsk/Sanofi I still reckon will be first in the vaccine race, most experienced in vaccines, has the other runners start falling at the first fence" PFE? | geckotheglorious | |
14/10/2020 09:00 | Gsk been raised to BUY this morning by Intron Health, target 1700p. | montyhedge | |
14/10/2020 08:57 | Gsk/Sanofi I still reckon will be first in the vaccine race, most experienced in vaccines, has the other runners start falling at the first fence. | montyhedge | |
14/10/2020 08:51 | Given that some kind of Covid-19 vaccine emerges, it seems that it may take a long time before a mass vaccination program can be undertaken. If the program with limited supply is to be staged first across age groups and critical workers, my thoughts are that very old people (who are apparently more at risk) should not be 'first in the queue'. Instead, they should be shielded until its their turn. Its the younger people that should be vaccinated first. Students (18+) up to 35 (critical to maintain the economy) and beyond. The reason is, this group mixes more socially, is more mobile in the community and doesn't seem to 'obey the rules', becoming 'super-spreaders'. Once this step has reduced infection rates in that group, and once more vaccine supplies are available, then the program could move on to further protect the aged and more vulnerable. | tradermichael | |
14/10/2020 08:44 | Another COVID vaccine pause announced yesterday, two this week. GSK getting some support perhaps as a result. | essentialinvestor | |
14/10/2020 08:42 | I'll be avoiding the flu jab myself.. Maintain healthy diet and extra Vitamin C/Vitamin d, Elderberry syrup etc to boost my immune system. | geckotheglorious | |
13/10/2020 16:47 | Ok thanks. | montyhedge | |
13/10/2020 14:01 | monty, Tesco Brooklands. They are only accepting those eligible for a free flu jab on the NHS atm (I think). | essentialinvestor | |
13/10/2020 14:00 | You were lucky shortage of flu vaccine. | montyhedge | |
13/10/2020 14:00 | Good luck with that! | tradermichael | |
13/10/2020 13:55 | Have my flu jab later today, joy, not. | essentialinvestor | |
13/10/2020 13:53 | Based on current data, it seems as though SARS-CoV-2 mutates much more slowly than the seasonal flu. Specifically, SARS-CoV-2 seems to have a mutation rate of less than 25 mutations per year, whereas the seasonal flu has a mutation rate of almost 50 mutations per year. Given that the SARS-CoV-2 genome is almost twice as large as the seasonal flu genome, it seems as though the seasonal flu mutates roughly four times as fast as SARS-CoV-2. The fact that the seasonal flu mutates so quickly is precisely why it is able to evade our vaccines, so the significantly slower mutation rate of SARS-CoV-2 gives us hope for the potential development of effective long-lasting vaccines against the virus. | tradermichael | |
13/10/2020 11:51 | Yes, but for maximum hysteria value, its not featured on a tabloid or broadsheet front page yet! spud | spud | |
13/10/2020 11:39 | Spud Post 22327 "The next headline when not enough people are being reinfected will be the Mutating Virus!" Covered already surely? "A comparison of genetic codes showed "significant differences" between each virus variant" ie a mutation! | geckotheglorious | |
13/10/2020 11:24 | The next headline when not enough people are being reinfected will be the Mutating Virus! Don't forget, you heard it here first..spud | spud | |
13/10/2020 10:51 | It could be a one in a million event, we don't know. Neither do we known how long any immunity lasts following infection. As many people were infected in March and there are exceptionally few confirmed cases of reinfection, it appears to be 6 months or longer. | essentialinvestor | |
13/10/2020 10:37 | It's the media's dream headline! I'm not getting sucked in as the odds are so low as to be uncalculable. If the media can spin this for another 12 months, they'll use every tenuous weapon in their armoury. spud | spud |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions